Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma … Read more
Celltrion Inc (068270) - Total Assets
Latest total assets as of September 2025: ₩21.08 Trillion KRW
Based on the latest financial reports, Celltrion Inc (068270) holds total assets worth ₩21.08 Trillion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Celltrion Inc - Total Assets Trend (2007–2024)
This chart illustrates how Celltrion Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Celltrion Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Celltrion Inc's total assets of ₩21.08 Trillion consist of 26.5% current assets and 73.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 4.7% |
| Accounts Receivable | ₩1.22 Trillion | 5.8% |
| Inventory | ₩2.77 Trillion | 13.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.79 Trillion | 8.5% |
| Goodwill | ₩11.91 Trillion | 56.6% |
Asset Composition Trend (2007–2024)
This chart illustrates how Celltrion Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celltrion Inc's current assets represent 26.5% of total assets in 2024, a decrease from 50.3% in 2007.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2024, up from 2.6% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 64.0% of total assets, an increase from 1.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 56.6% of total assets.
Celltrion Inc Competitors by Total Assets
Key competitors of Celltrion Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
CohBar Inc
NASDAQ:CWBR
|
USA | $12.51 Million |
|
Glorywin Entertainment Group Inc
PINK:GWIN
|
USA | $0.00 |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Celltrion Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Celltrion Inc generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Celltrion Inc generates $ 2.01 in net profit.
Celltrion Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 1.77 | 2.38 |
| Quick Ratio | 0.70 | 0.85 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩1.53 Trillion | ₩ 2.34 Trillion | ₩ 1.46 Trillion |
Celltrion Inc - Advanced Valuation Insights
This section examines the relationship between Celltrion Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.70 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | ₩21.06 Trillion |
| Market Capitalization | $19.24 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Celltrion Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Celltrion Inc's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Celltrion Inc (2007–2024)
The table below shows the annual total assets of Celltrion Inc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩21.06 Trillion | +5.71% |
| 2023-12-31 | ₩19.92 Trillion | +238.06% |
| 2022-12-31 | ₩5.89 Trillion | +3.83% |
| 2021-12-31 | ₩5.67 Trillion | +13.03% |
| 2020-12-31 | ₩5.02 Trillion | +30.07% |
| 2019-12-31 | ₩3.86 Trillion | +10.18% |
| 2018-12-31 | ₩3.50 Trillion | +6.35% |
| 2017-12-31 | ₩3.29 Trillion | +9.01% |
| 2016-12-31 | ₩3.02 Trillion | +9.96% |
| 2015-12-31 | ₩2.75 Trillion | +18.34% |
| 2014-12-31 | ₩2.32 Trillion | +17.38% |
| 2013-12-31 | ₩1.98 Trillion | +14.17% |
| 2012-12-31 | ₩1.73 Trillion | +23.14% |
| 2011-12-31 | ₩1.41 Trillion | +21.80% |
| 2010-12-31 | ₩1.16 Trillion | +106.63% |
| 2009-12-31 | ₩559.20 Billion | +12.01% |
| 2008-12-31 | ₩499.26 Billion | +712.34% |
| 2007-12-31 | ₩61.46 Billion | -- |